Seaport Therapeutics announced the appointment of Dr. Sharon Mates to its board of directors. Mates served as co-founder, chairman and chief executive officer of Intra-Cellular Therapies from June 2002 until Johnson & Johnson acquired the company in 2025 for approximately $14.6 billion.

Under Mates' leadership, Intra-Cellular Therapies developed medicines for mental health disorders including bipolar disorder, depression and schizophrenia. The company received FDA approval for its antipsychotic CAPLYTA, which generated more than $1.5 billion in sales prior to the J&J acquisition.

"Sharon is an exceptional biotech entrepreneur and leader whom I have admired for years," said Daphne Zohar, founder and CEO of Seaport Therapeutics. "Her significant experience, intellectual curiosity, deep industry relationships, and genuine appreciation for our patient-centered approach will meaningfully support Seaport's mission to develop life-changing treatments for patients with depression, anxiety, and other neuropsychiatric disorders."

Mates currently serves on the boards of Medincell (Euronext: MEDCL) and Benitec (NASDAQ: BNTC). She is forming a new company focused on inflammation, metabolism and other indications. Mates holds a Ph.D. from the University of Washington and completed postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School.

Seaport Therapeutics is a clinical-stage company developing neuropsychiatric medicines using its Glyph platform. The company is a founded entity of PureTech Health (NASDAQ: PRTC, LSE: PRTC).